Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies is poised for potential success with their lead drug, OST-HER2, which has shown promise in preventing or delaying recurrence in osteosarcoma patients. The company has multiple upcoming catalysts, such as data updates, regulatory meetings, and potential approval decisions, which could provide significant financial opportunities. Additionally, the company has received orphan, fast track, and rare pediatric disease designations, which could expedite development and review. With a planned global Phase 3 trial and potential monetization of a Priority Review Voucher, OS Therapies has a positive outlook for the future.

Bears say

OS Therapies is facing multiple risks that could impact their future success, including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks. Additionally, despite their coordinated regulatory engagement and potential for an accelerated approval pathway, the company's Phase 3 trial for OST-HER2 in metastatic osteosarcoma will not take place until Q3 2026, leading to a potential market entry in the second half of that year. These factors contribute to a negative outlook on the stock's future performance and growth potential.

OSTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, OSTX has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.